SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-000822 to Bon Natural Life Ltd (BON)

Bon Natural Life Ltd
Date: Jan. 27, 2025 · CIK: 0001816815 · Accession: 0000000000-25-000822

AI Filing Summary & Sentiment

File numbers found in text: 333-283333

Date
January 27, 2025
Author
Not clearly detected
Form
UPLOAD
Company
Bon Natural Life Ltd

Letter

January 27, 2025 Yongwei Hu Chief Executive Officer Bon Natural Life Limited C601, Gazelle Valley, No.69 Jinye Road Xi’an Hi-tech Zone, Xi’an, China Re:Bon Natural Life Limited Amendment No. 1 to Registration Statement on Form F-1 Filed January 16, 2025 File No. 333-283333 Dear Yongwei Hu: We have reviewed your amended registration statement and have the following comments. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our November 26, 2024 letter. Amendment No. 1 to Registration Statement on Form F-1 Cover Page 1.We note your response to prior comment 1 and amended disclosure stating you are now offering Ordinary Units. Please revise the cover page caption to clarify that you are registering up to 15,000,000 Class A Ordinary Shares, including the shares underlying the Pre-Funded Warrants and Series A and B Warrants, as some of the Ordinary Shares are not dependent on exercising the Warrants. 2.We note your disclosure that your "offering may be extended by written agreement of the Company and the placement agent." Please revise to provide a certain date your offering will terminate. Refer to Item 501(b)(8)(iii) of Regulation S-K.

January 27, 2025 Page 2 Please contact Daniel Crawford at 202-551-7767 or Suzanne Hayes at 202-551-3675 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Cassi Olson, Esq.

Show Raw Text
January 27, 2025
Yongwei Hu
Chief Executive Officer
Bon Natural Life Limited
C601, Gazelle Valley, No.69 Jinye Road
Xi’an Hi-tech Zone, Xi’an, China
Re:Bon Natural Life Limited
Amendment No. 1 to Registration Statement on Form F-1
Filed January 16, 2025
File No. 333-283333
Dear Yongwei Hu:
            We have reviewed your amended registration statement and have the following
comments.
            Please respond to this letter by amending your registration statement and providing
the requested information. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing any amendment to your registration statement and the information
you provide in response to this letter, we may have additional comments. Unless we note
otherwise, any references to prior comments are to comments in our November 26,
2024 letter.
Amendment No. 1 to Registration Statement on Form F-1
Cover Page
1.We note your response to prior comment 1 and amended disclosure stating you are
now offering Ordinary Units. Please revise the cover page caption to clarify that you
are registering up to 15,000,000 Class A Ordinary Shares, including the shares
underlying the Pre-Funded Warrants and Series A and B Warrants, as some of the
Ordinary Shares are not dependent on exercising the Warrants.
2.We note your disclosure that your "offering may be extended by written agreement of
the Company and the placement agent." Please revise to provide a certain date your
offering will terminate. Refer to Item 501(b)(8)(iii) of Regulation S-K.

January 27, 2025
Page 2
            Please contact Daniel Crawford at 202-551-7767 or Suzanne Hayes at 202-551-3675
with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Cassi Olson, Esq.